UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2022

Longboard Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

1-40192

(Commission File Number)

Delaware (State or Other Jurisdiction of Incorporation)

4275 Executive Square, Suite 950 La Jolla, CA (Address of Principal Executive Offices) 84-5009619 (IRS Employer Identification No.)

> 92037 (Zip Code)

Registrant's Telephone Number, Including Area Code: (619) 592-9775

 $$\mathbf{N}/\mathbf{A}$$ (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

	Trading	
Title of each class	Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.0001 per share	LBPH	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company \boxtimes

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 Regulation FD Disclosure.

On December 5, 2022, Longboard Pharmaceuticals, Inc. (the "Company") announced positive topline data from a Phase 1 clinical study evaluating the central nervous system ("CNS") pharmacokinetics ("PK") and pharmacodynamics ("PD") of LP352, an oral, centrally acting 5-hydroxytryptamine 2C receptor subtype superagonist, in healthy volunteers. In connection with the data release, the Company compiled a presentation entitled "The Potential of LP352", which includes LP352 preclinical and clinical summary results to date, including the data from the Phase 1 clinical study referenced above.

A copy of the presentation is furnished as Exhibit 99.1. For important information about forward-looking statements, see the slide titled "Forward-Looking Statements" in Exhibit 99.1 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission ("SEC") made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 8.01 Other Events.

As noted in Item 7.01, on December 5, 2022, the Company announced positive topline data from its Phase 1 clinical study evaluating CNS PK and PD of LP352 in healthy volunteers.

The primary objectives of the open-label, Phase 1 study are to assess the central nervous system ("CNS") pharmacokinetics ("PK") and pharmacodynamics ("PD") of orally administered LP352 in healthy adult male and female participants (n=10 in each Cohort). Objectives include the characterization of plasma and cerebrospinal fluid ("CSF") PK, the characterization of safety and tolerability of doses with titration and taper, and the assessment of the PK-PD relationships between plasma and CSF exposure, and PD endpoints of safety and efficacy, including quantitative electroencephalogram ("qEEG") endpoints. Two doses (Cohort 1 = 6 mg and Cohort 2 = 12 mg) of LP352 three times daily were tested over a 16-day period in addition to a screening and follow-up period. Additional cohorts of the study are ongoing.

Topline data for Cohorts 1 and 2 reported include:

- LP352 exhibited a strong correlation between plasma and CSF PK concentration, which increased in a dosedependent and consistent manner
- LP352 demonstrated early qEEG changes, and sustained effects on qEEG activity after continuous dosing in a dosedependent manner indicating receptor engagement
- Favorable safety and tolerability results were observed in the study, with adverse events generally consistent with previous clinical studies

In addition, LP352 is being designed and dose-optimized for developmental and epileptic encephalopathies ("DEEs"). The Company is currently assessing alternative strategies to elucidate the benefits and feasibility of certain twice daily ("BID") dosing formulations. This work is ongoing and the Company expects to complete this assessment prior to initiating a Phase 3 clinical study for LP352 for DEEs.

Forward Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to Company's expectations regarding completing its BID assessment prior to initiating a Phase 3 clinical study for LP352 for DEEs. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they prove incorrect or do not fully materialize, could cause the Company's results to differ materially from those expressed or implied by such forward-looking statements, including, but not limited to, risks and uncertainties related to: topline data may not reflect the complete or final results of a particular study or trial, and are subject to change; the Company's ability to advance, obtain regulatory approval of and ultimately commercialize its product candidates; the timing and results of preclinical and clinical trials; the risk that positive results in a clinical trial may not be replicated in subsequent trials or successes in early stage clinical trials may not be predictive of results in later stage trials and preliminary interim data readouts of ongoing trials may show results that change when such trials are completed; the Company's ability to fund development activities and achieve development goals; the Company's ability to protect its intellectual property; the direct and indirect impacts geopolitical and macroeconomic events on the Company's business; and other risks and uncertainties described under the heading "Risk Factors"

in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, its subsequently filed Quarterly Reports on Form 10-Q, and the other documents the Company files from time to time with the SEC. These forward-looking statements speak only as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Slide presentation entitled "The Potential of LP352"
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Longboard Pharmaceuticals, Inc.

Date: December 5, 2022

By:_____

/s/ Kevin R. Lind

Kevin R. Lind President and Chief Executive Officer

Exhibit 99.1



Corporate Presentation -The Potential of LP352

December 2022

Forward-Looking Statements

This presentation contains forward-looking statements about Longboard Pharmaceuticals, Inc. ("we," "Longboard" or the "Company"), including statements regarding: our future results of operations and financial position; business strategy; the timing, costs, conduct and results of our preclinical studies and clinical trials for our product candidates, such as our expectations regarding our PACIFIC Study and data from our Phase 1 Open-Label PK/PD study; the timing and likelihood of regulatory filings and approvals for our product candidates, such as our pre-IND meeting for LP659; our intellectual property; our ability to obtain regulatory approval and commercialize our product candidates; the potential of LP352, including to limit adverse events associated with currently available non-selective ASMs, make a difference across a range of DEEs, and be a best-in-class ASM, including through BID dosing; and other statements that are not historical facts, including statements that may include words such as "will", "may", "can", "intend", "plan", "expect", "believe", "potential" and similar words.

For such statements, we claim the protection of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: our limited operating history; net losses; our expectation that we will incur net losses for the foreseeable future, and that we may never be profitable; our need for additional funding and related risks for our business, product development programs and future commercialization activities; the timing and success of clinical trials we conduct; topline data may not reflect the complete or final results of a particular study or trial, and are subject to change; the ability to obtain and maintain regulatory approval of our product candidates; the ability to commercialize our product candidates; our ability to compete in the marketplace; risks regarding our license and dependencies on others; our ability to obtain and maintain intellectual property protection and freedom to operate for our product candidates; our ability to manage our growth; and other risks and factors disclosed in our filings with the U.S. Securities and Exchange Commission (the "SEC"). We operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. The forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Except as required by law, we assume no responsibility for the accuracy and completeness of the forward-looking statements, and we undertake no obligation to update any forward-looking statements after the date of this presentation to

Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, research, publications, surveys and other data obtained from third-party sources and Longboard's own internal estimates and research. While Longboard believes these third-party studies, research, publications, surveys and other data to be reliable as of the date of this presentation, it has not been independently verified, and makes no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources.

This presentation discusses product candidates that have not yet been approved for marketing by the U.S. Food and Drug Administration.



Longboard's Pipeline of Next Generation GPCR Programs

Program	MOA	Therapeutic Area	Preclinical	Ph I	Ph II	Ph III	Anticipated Milestones
							 Ph 1 data at medical mtg H1 2022
LP352	5-HT2C Superagonist	DEEs and other refractory epilepsies					Ph 1 CSF PK/PD qEEG data - Q4 2022
							Ph 1b/2a PACIFIC Study Data - H2 2023
LP659	S1P Receptor Modulator	Multiple neurological diseases					Pre-IND Meeting – Q4 2022

• We hold rights to other product candidates, including LP143 and nelotanserin, through the Arena License Agreement

• We are eligible to receive royalties of 9.5% - 18.5% on sales of lorcaserin if approved for commercialization*



LONGBOARD PHARMACEUTICALS

* Through the Royalty Purchase Agreement
Definitions: DEEs=developmental and epileptic encephalopathies; S1P = sphingosine 1-phosphate; PK=pharmacokinetics; PD=pharmacodynamics; EEG = electroencephalogram

LP352 has the Potential to Make a Difference Across a Range of DEEs

Penetrates the brain in a dose-dependent, consistent and sustained manner

5-HT2 proof-of-concept observed across multiple DEEs and seizures types, however there are safety and dosing considerations with other compounds:

 LP352 is the *only* 5-HT2C agonist being **dose optimized** to address this patient population

LP352 demonstrated **predictive efficacy in several pre-clinical seizure models**:

• Multiple zebrafish and rodent models

Demonstrated consistent CNS engagement through:

- Transient prolactin increases
- Sustained qEEG activity

Ph 1 data support potential best-in-class profile:

- SAD/MAD
- CSF/EEG

Enrolling the Ph 1b/2a **PACIFIC study** in patients 12-65 years old with DEE diagnosis

- No echocardiograms
- Evaluating broad range of seizure types across DEEs

Strong IP protection through 2041*

*Composition of matter through 2036 with potential for PTE & PTA (2041) Definitions: DEEs=developmental and epileptic encephalopathies; CSF = cerebrospinal fluid; EEG = electroencephalogram

LP352 Greater Selectivity and Specificity

The product of 20 years of world-class GPCR research and optimization



The Potential of 5-HT2C Superagonist LP352

A potential best-in-class serotonin receptor agonist antiseizure product candidate that is designed to be highly selective and being dose-optimized to treat a broad range of DEEs effectively and safely

The Potential of LP352

?	Greater Selectivity and Specificity	 5-HT2 agonist designed to only bind to the 5-HT2C receptor* 5-HT2 agonist that has no detected activity at receptors associated with significant adverse side effects: 5-HT2B (valvular heart disease and PAH) & 5-HT2A (psychiatric: insomnia, hallucinations, euphoria)
~	Preclinical Validation	 Reduces seizure activity in model of neuronal hyperexcitability in zebrafish Reduced epileptiform activity in fish and rodent models of disinhibition Reduced duration and number of epileptiform events in zebrafish model of Dravet Syndrome
?	Clinical Validation SAD/MAD	 In general, favorable safety and tolerability observed. Adverse events generally consistent with expected effects of serotonergic medications No observed food effect Potential prolactin biomarker which increased in a dose dependent and transient manner
~	Clinical Validation CSF/EEG **	 Favorable safety and tolerability results observed, adverse events generally consistent with previous clinical studies Plasma and CSF PK concentration increased in a dose dependent and consistent manner Demonstrated effects on qEEG activity within first few dose(s) Demonstrated sustained dose-dependent effects on qEEG activity after continuous dosing, thus indicating receptor engagement

5-HT2 Evolution in Rare Epilepsies **Designed & Being Dose-Optimized** Weight Loss Drugs Repurposed for DEEs **FINTEPLA® DS** Lorcaserin **Compound:** LP352 (fenfluramine, ZX008) (Marketed as BELVIO) • Designed to avoid the cardiac effects seen Designed to be a next-generation selective 5-HT2C • Approved for weight loss in 1973, with fenfluramine superagonist became popular in 1990s in Fen-Phen • Approved for weight loss in 2012 (never approved in combo) • Dose optimization for DEEs (currently TID) • No significant difference in major adverse **History:** • Withdrawn due to significant cardiac • BID formulation work ongoing, expected for Ph 3 cardiovascular outcomes versus placebo¹ toxicity (1997) • Withdrawn from market 2020; increased • No echocardiograms in PACIFIC study Repurposed for DEEs at lower dose occurrence of cancer in safety clinical trial • Approved for the treatment of seizures FDA Expanded Access Program in Dravet, Current • Ph 1b/2a clinical trial in multiple DEEs with Dravet & LGS (REMS required Status: Ph 3 Dravet with echocardiograms), Ph 3 CDD Fintepla (lorcaserin HCI) Tablets 🕑 2.2 mg/mL oral solution 10 mg IIIIII LONGBOARD PHARMACEUTICALS *R=undisclosed 1 = CAMELLIA-TIMI 61

LP352 Designed to be a Next Generation 5-HT2C with Greater Selectivity and Specificity

	Serotonin Receptor Subtype	EC _{50,} nM	Ki, nM	Selectivity 5-HT2C vs 5-HT2B	Selectivity 5-HT2C vs 5-HT2A	Potential Adverse Events Per Receptor Subtype
	5-HT2C	~120	~50	>200x	>200x	CNS, GI
LP352 5-HT2C Superagonist	5-HT2B	>10,000	>10,000			n/a
5-1112C Superagonist	5-HT2A	>10,000	>10,000			n/a
Nordexfenfluramine	5-HT2C	72.4	10.4	0.94x	11.5x	CNS, GI
(an active metabolite of	5-HT2B	25.7	9.8			Cardiac, Pulmonary
fenfluramine) ¹	5-HT2A	1778	120.2			Psychiatric
	5-HT2C	39	13	11.3x	7.1x	CNS, GI
Lorcaserin ²	5-HT2B	2380	147			n/a
	5-HT2A	553	92			Psychiatric

LP352 selectivity may limit off-target effects associated with currently available non-selective ASMs

1 Third party study previously commissioned by Arena, 2 BELVIQ FDA approved prescribing information o6/2012; Note: The above table is for illustrative purposes only and is not a head-to-head comparison. Differences exist between in vitro study designs and methodologies, and caution should be exercised when comparing data across studies Definitions: CNS= Central nervous system ; GI = Gastrointestinal; ASM = anti-seizure medication



LONGBOARD PHARMACEUTICALS


LP352 Inhibited Seizure Activity in Multiple Preclinical Models

	Corneal Kindling	Pentylenetetrazol (PTZ) (i.v.)	Scn1a ^{A1783V/WT} Transgene	<i>scn1lab</i> Transgene	Ethyl ketopentenoate (EKP)	Kainic acid (KA)
Model	Partial (focal) limbic seizures	Acute seizure	Genetic model of Dravet Syndrome	Genetic model of Dravet Syndrome	Generalized seizure	Acute and chronic seizure
Species	mouse	mouse	mouse	zebrafish	zebrafish	zebrafish
Activity	-	+	-	+	+	+


Potential ASMs are assayed in multiple relevant preclinical models based on the compound's MOA. Models are conducted utilizing wide range panels that typically produce a mix of positive and negative results. The above are a subset of preclinical assays conducted with LP352. Preclinical models are not necessarily predictive of clinical efficacy or regulatory approval.

LP352 Significantly Reduced Epileptiform Frequency & Duration in the Zebrafish *scn1lab* Model of Dravet Syndrome

FREQUENCY OF EPILEPTIFORM EVENTS



LP352 demonstrated 85% reduction of epileptiform events




DURATION OF EPILEPTIFORM ACTIVITY

LP352 demonstrated 84% reduction of epileptiform duration



LP352 Significantly Improved Seizure Activity in the Zebrafish EKP Epilepsy Model

Epileptiform brain activity (LFPs) in the EKP model




LP352 demonstrated $\sim 69\%$ reduction in seizure activity



LP352 Significantly Reduced Seizure Activity in the Zebrafish Kainic Acid Epilepsy Model

LP352 Normalized Power Spectral Density



LP352 demonstrated $\sim 82\%$ reduction of seizure activity





LP352 Demonstrated Dose-Dependent Improvement in Time to Clonic Seizures in PTZ Mouse Model

Effect of LP352 on the Threshold for Seizures Induced by the Timed Intravenous Infusion of PTZ in Male Mice

			PTZ Dose (mg/kg, Mean ± S.E.M)			
Compound	Animal Weight (Grams, Mean ± S.E.M.)	Time of Test	First Twitch	Clonus		
Vehicle Control	32.7 ± 0.7	0.5 hr	25.1 ± 1.5	26.4 ± 1.6		
LP352 3mg/kg	31.4 ± 0.4	0.5 hr	26.5 ± 0.8	30.3 ± 1.1		
LP352 10mg/kg	31.8 ± 0.4	0.5 hr	28.7 ± 0.7	32.3 ± 1.2**		
**m < 0.01						





LP352 Ph 1 Multiple Ascending Dose (MAD) Results Favorable Safety & Tolerability Results Observed

Treatmen	t-Emergent Adverse Eve	nts by Preferred Term Occur	rring in \geq 2 Subjects in Any	Treatment Group – MAD (S	Safety Set)
Term n(%) E3 mg (N=6)6 mg (N=6)12 mg (N=7)18 mg (N=6)(N=8)Subjects with at least 1 TEAE5 (83.3) 96 (100) 296 (85.7) 396 (100) 554 (50.0) 8teadache2 (33.3) 22 (33.3) 42 (28.6) 54 (66.7) 51 (12.5) 1omnolence1 (16.7) 11 (16.7) 14 (57.1) 43 (50.0) 50vizziness03 (50.0) 32 (28.6) 32 (33.3) 20dicturition Urgency1 (16.7) 101 (14.3) 15 (83.3) 50vizziness Postural001 (14.3) 15 (83.3) 50vizziness Postural002 (28.6) 34 (66.7) 40virthosati (Hpyotension002 (28.6) 31 (16.7) 11 (12.5) 1arasethesia001 (14.3) 12 (33.3) 201 (12.5) 1arasethesia01 (16.7) 12 (28.6) 31 (16.7) 11 (12.5) 1arasethesia01 (16.7) 12 (28.6) 31 (16.7) 101 (12.5) 1arasethesia001 (14.3) 13 (50.0) 500virthy02 (33.3) 202 (33.3) 200virthstict HResponse0002 (33.3) 200virthstict HResponse0002 (33.3) 200virthstict HResponse0002 (33.3) 200virthstict HResponse0000000 </th <th></th>					
					Pooled Placebo (N=8)
	5 (83.3) 9	6 (100) 29	6 (85.7) 39	6 (100) 55	4 (50.0) 8
Headache	2 (33.3) 2	2 (33.3) 4	2 (28.6) 5	4 (66.7) 5	1 (12.5) 1
Somnolence	1 (16.7) 1	1 (16.7) 1	4 (57.1) 4	3 (50.0) 5	0
Dizziness	0	3 (50.0) 3	2 (28.6) 3	2 (33.3) 2	0
Micturition Urgency	1 (16.7) 1	0			0
Dizziness Postural	0	0		5 (83.3) 5	0
Diarrhoea	1 (16.7) 1	4 (66.7) 4	1 (14.3) 1	0	0
Orthostatic Hypotension	0	0	2 (28.6) 3	4 (66.7) 4	0
Constipation	1 (16.7) 1	1 (16.7) 1	2 (28.6) 3	1 (16.7) 1	1 (12.5) 1
Nausea	1 (16.7) 1	0	1 (14.3) 1	2 (33.3) 2	1 (12.5) 1
Paraesthesia	0	1 (16.7) 1	2 (28.6) 3	1 (16.7) 1	0
Chills	0	0	1 (14.3) 1	3 (50.0) 5	0
Anxiety	0	2 (33.3) 2	0	2 (33.3) 2	0
Orthostatic HR Response Increased	0	0	0		1 (12.5) 1
Dysmenorrhoea	1 (16.7) 1	0	0	2 (33.3) 2	1 (12.5) 1
Fatigue	0	2 (33.3) 2	0	0	0
Vessel Puncture Site Bruise	0	0	0	2 (33.3) 2	0
Hypotension	0	2 (33.3) 2	0	0	0

• Majority of AEs were mild to moderate (most common was headache)


• AEs generally consistent with expected CNS effects and expected effects of serotonergic drugs

• At the maximum planned dose, a single SAE of anxiety was reported two days after last dose of study drug and subsequently resolved

LP352 Ph 1 Single Ascending Dose (SAD) Results Favorable Pharmacokinetics and Pharmacodynamics Results Observed

Single Ascending Dose & Single-Dose Food Effect (N=40)

Percent Change from Baseline in 2-Hour Prolactin Concentration Across All Dose Groups Under Fasted Conditions




LP352 Demonstrated No Meaningful Food Effect

$\begin{array}{c ccccccccccccccccccccccccccccccccccc$						
	n	Fed	n	Fasted		
C _{max} (ng/mL)	6		6	0.00		
AUC _{0-last} (h*ng/mL)	6	61.9 [33.4, 114.7]	6	49.2 [26.6, 91.2]		
AUC _{0-inf} (h*ng/mL)	6	63.6 [34.7, 116.6]	6	51.0 [27.8, 93.4]		

LP352 Ph 1 MAD Results Favorable Pharmacokinetics and Pharmacodynamics Results Observed

Multiple Ascending Dose & Dose Titration (N=43)

Pharmacodynamics: Boxplot of Percent Change From Baseline in Prolactin Concentration with Dose on Day 1 at 2 Hrs -MAD and Dose Titration (Safety Population)



Key Summary of LP352 Pharmacokinetic Parameters by Cohort (Day 14) -MAD and Dose Titration (PK Analysis Population)

Parameter (Unit)	MAD 12 mg (N = 7)
C _{max} (ng/mL) (Mean)	44.9
T _{max} (h) (Median)	1.3
AUC _{0-inf} (h*ng/mL) (Mean)	330
T _{1/2} (h) (Mean)	6.0

LP352 102: A Phase 1 PK/PD CNS Study in Adult Healthy Volunteers

1	Up-Titration	Daily Dosing of Liquid Formulation	Taper Down	Follow-up
28 Days	Days 1-2	Days 3-11 (target treatment)	Day 11 (start taper after AM dose)	Day 25
Screening		Cohort 1 (n=10) 6 mg TID		
		Cohort 2 (n=10) 12 mg TID		
		Additional Cohorts Ongoing		

A Phase 1, Open-label Study to Assess Central Nervous System Pharmacokinetics (PK) and Pharmacodynamics (PD) of Orally Administered LP352

Key Study Objectives:

- Characterize the plasma and CSF PK
- Characterize the safety and tolerability of the doses with titration and taper
- Assess the PK-PD relationships between plasma and CSF exposure and PD endpoints of safety and efficacy, including qEEG endpoints as indicators of CNS target engagement

Plasma:

- Samples Days 1-11 (and taper)
- PK parameters: Cmax, Tmax and AUCtau

CSF:


- Samples Day 11
- PK parameters: Cmax, Tmax and AUCtau

EEG:

- Serial EEGs Days -1, 1, 3 & 10 (trough Day 16)
- EEG parameters: Five-minute resting EEG with eyes closed and five-minute resting EEG with eyes open performed with the participant seated comfortably in a sound-attenuated room
- Resting EEG evaluated by spectral and coherence analysis, including spectral amplitudes and coherences in clinical frequency bands




Steady State Plasma & CSF Concentrations for LP352 (6mg & 12mg) 12 mg TID Exceeded Ki Value for 5-HT2C Activity throughout Dosing Interval*



The vast majority of participants in the 12 mg TID cohort achieved plasma and CSF levels above the relevant Ki throughout the dosing period.



Cmax and AUC CSF vs. Plasma Correlations Strong Correlation Between Plasma and CSF PK Parameters*





5-Minute Resting qEEG Spectral Amplitudes in Clinical Frequency Bands (Days -1,1 and 3)

LP352 Demonstrated Early qEEG Changes*

Eyes Clos	cu	6 m		D					D		_			D		
Band	Spatial			Day-1					Day 1					Day 3		
	Location	-1hr	+1hr	+2hr	+4hr	+8hr	-1hr	+1hr	+2hr	+4hr	+8hr	-1hr	+1hr	+2hr	+4hr	+8hr
Delta	Frontal															
	Central															
	Temporal															
	Parietal															
	Occipital															
Alpha 1	Frontal												I			ł
	Central										+					ł
	Temporal							•					ł		ł	
	Parietal												+			ł
	Occipital							+			+	4				
	Frontal															
Alpha 2	Central														+	
	Temporal															
	Parietal															
	Occipital															
	Frontal														1	
	Central															
Beta 1	Temporal															
	Parietal													•		
	Occipital															
	Frontal															
	Central									1			1			
Beta 2	Temporal															
	Parietal															
	Occipital							Ŧ								
	Frontal								Ţ			+	1	Ŧ	L.	
	Central								1				Ť	Ţ	T.	
Beta 3	Temporal		_													
	Parietal			_	_			_	Ŧ		_					
	Occipital															

Band	sed Spatial Location	12 mg Day-1				Day 1				Day 3						
		-1hr	+1hr	+2hr	+4hr	+8hr	-1hr	+1hr	+2hr	+4hr	+8hr	-1hr	+1hr	+2hr	+4hr	+8hr
Delta	Frontal															
	Central															
	Temporal															
	Parietal															
	Occipital															
Alpha 1	Frontal															
	Central															
	Temporal															
	Parietal															
	Occipital															
	Frontal															
	Central												+			
Alpha 2	Temporal												+			
	Parietal												ŧ	+		
	Occipital												•			
	Frontal										1					
	Central											+				
Beta 1	Temporal											•		+		
	Parietal								+			•		+		
	Occipital								•	1		•		•		
Beta 2	Frontal															
	Central														I	
	Temporal							+								
	Parietal															
	Occipital															
Beta 3	Frontal															
	Central												Ţ	Ŧ	Ţ	Ţ
	Temporal															
	Parietal			_										Ŧ	Ţ	Ţ
	Occipital					_										

*Topline data from 102 study

LONGBOARD PHARMACEUTICALS

Small and large salient contrasts (>10%, >15%) are indicated by light and heavy arrows (blue=decrease, red=increase) respectively. Small and large salient Cohen's d values (>0.5, >0.8) are indicated by light and dark shading (blue=decrease, orange=increase) respectively.

5-Minute Resting qEEG Spectral Amplitudes in Clinical Frequency Bands (Days 10 and 16)

LP352 Demonstrated Sustained Effects on qEEG Activity After Continuous Dosing in a Dose-Dependent Manner, Thus Indicating Receptor Engagement*

Eyes Closed		6 m	g				
	Spatial		Day 16				
Band	Location	-1hr	+1hr	+2hr	+4hr	+8hr	-1hr
Delta	Frontal						
	Central						
	Temporal			•			
	Parietal						
	Occipital						
	Frontal		+		+	+	
	Central		+	+	+	+	
Alpha 1	Temporal		+	↓	↓	+	
	Parietal		+	+	+	+	
	Occipital		+	+	+		
	Frontal						
	Central				+		
Alpha 2	Temporal		+	+	+		
	Parietal					T	
	Occipital						
	Frontal						
	Central						
Beta 1	Temporal	L 🕈					
	Parietal	↓					
	Occipital						
Beta 2	Frontal						
	Central						
	Temporal						
	Parietal		+			•	
	Occipital						
	Frontal	+	+	¥	↓		
	Central		+	+	+		
Beta 3	Temporal						
	Parietal		+	↓	↓ ·	L L	
	Occipital			+			

*Topline data from 102 study

Eyes Closed		12 r	12 mg Day 10 Day 16									
	Spatial		Day 10									
Band	Location	-1hr	+1hr	+2hr	+4hr	+8hr	-1hr					
Delta	Frontal				-							
	Central	- +			•	•	•					
	Temporal	- -				-						
	Parietal	•				•	•					
	Occipital	- -										
Alpha 1	Frontal	•	+	•	+	•	•					
	Central	- i 🗼	•				i 🗼					
	Temporal	T I	- -		+	I	i 🗼					
-	Parietal		Ŧ		I							
	Occipital		+	•	+	+						
	Frontal	•	1	+	+	I						
	Central		+	•		+	İ					
Alpha 2	Temporal	_ ↓	+	+	+	+	1					
-	Parietal		+	•	+	•	1					
	Occipital	1	+	+	+	+						
	Frontal			•								
	Central											
Beta 1	Temporal	1		•								
	Parietal			•								
	Occipital											
Beta 2	Frontal											
	Central					+	+					
	Temporal					+						
	Parietal											
	Occipital						+					
Beta 3	Frontal		+		+	+						
	Central	+	+	+	+	+						
	Temporal											
	Parietal		+	ŧ	+	+						
	Occipital		+	•	+	+						


LONGBOARD PHARMACEUTICALS

** On Day 16, all participants in Cohort 1 and 2 receive one final dose which was less than the full dose of 6 mg and 12 mg, respectively.

LP352-102 Phase 1 Study: Key Takeaways To Date

- First known study of its kind for a 5HT2 agonist (e.g. fenfluramine or lorcaserin)
- Favorable safety and tolerability results observed, with AEs generally consistent with previous clinical studies
- Plasma and CSF PK concentration increased in a dose-dependent and consistent manner
- Demonstrated effects on qEEG activity within first few dose(s)
- Demonstrated sustained dose-dependent effects on qEEG activity after continuous dosing, thus indicating receptor engagement
- In summary, we believe the data suggest that LP352 engaged neurotransmitter systems and altered the EEG spectrum

LP352 Ph 1b/2a PACIFIC Study in Patients with DEEs



A double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics of LP352 and

Key Efficacy Signals:

- EVALUATE reduction in seizures across a broad group of epilepsies
- IDENTIFY potential indications for pivotal studies
- ANALYZE concentration response to understand dosing in different seizure types and disorders

Key Exclusion Criteria:

Use of fenfluramine & lorcaserin

Basic Information:

Sites: ~30 sites Ages: \geq 12 to \leq 65 yrs old

Key Inclusion Criteria:

- Developmental and epileptic encephalopathies (DEEs) with ≥ 4 motor seizures per month in 3 mos. prior to screening and ≥ 4 motor seizures in the month of screening
- DEEs (multiple syndromes) may include Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis complex, CDKL5 deficiency disorder, SCN2A-related disorders, among others





* Maintenance Dose of LP352 (TID): 6 mg, 9 mg, 12 mg or placebo TID ** Up to a 15-day down-titration/taper period (reducing dose every 5 days) depending on the last maintenance dose



Thank you!

Nasdaq: LBPH

